Nutraceuticals in the management of patients with statin-associated muscle symptoms, with a note on real-world experience.
Natalie C WardJing PangJacqueline D M RyanGerald F WattsPublished in: Clinical cardiology (2018)
There is considerable evidence for the role of low-density lipoprotein cholesterol (LDL-C) in the development of atherosclerotic cardiovascular disease. Although statin therapy remains the most frequency prescribed medication to reduce LDL-C and lower risk of cardiovascular disease, a considerable number of patients develop muscle-related side affects. This review summarizes recent literature supporting the role of nutraceuticals as LDL-C-lowering therapy in statin-intolerant patients, with evidence from our own clinical practices.
Keyphrases
- cardiovascular disease
- low density lipoprotein
- end stage renal disease
- coronary artery disease
- skeletal muscle
- healthcare
- ejection fraction
- type diabetes
- systematic review
- chronic kidney disease
- cardiovascular events
- newly diagnosed
- primary care
- prognostic factors
- emergency department
- peritoneal dialysis
- patient reported outcomes
- physical activity
- sleep quality
- adverse drug